Source:http://linkedlifedata.com/resource/chebi/id/CHEBI:408174
| Predicate | Object |
|---|---|
| rdf:type | |
| skos:definition |
"An N-[2-hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl]formamide in which both of the stereocentres have R configuration. The active enantiomer of formoterol, it is administered by inhalation (generally as the tartrate salt) as a direct-acting sympathomimetic and bronchodilator for the treatment of chronic obstructive pulmonary disease (any progressive respiratory disease that makes it harder to breathe over time, such as chronic bronchitis and emphysema)." []
|
| skos:inScheme | |
| skos:prefLabel |
arformoterol
|
| skos:altLabel |
N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide
|
| skos:notation |
Beilstein:7861827 "Beilstein Registry Number",
ChEMBL:15324892 "PubMed citation",
ChemIDplus:67346-49-0 "CAS Registry Number",
CiteXplore:18990965 "PubMed citation",
CiteXplore:20214460 "PubMed citation",
CiteXplore:20406080 "PubMed citation",
DrugBank:67346-49-0 "CAS Registry Number",
DrugBank:DB01274 "DrugBank",
KEGG DRUG:67346-49-0 "CAS Registry Number",
KEGG DRUG:D07463 "KEGG DRUG",
Patent:US2011014246 "Patent"
|
| skos:broader | |
| skos:relatedSynonym |
C19H24N2O4,
arformoterol,
(-)-formoterol,
(R,R)-formoterol,
[H]C(=O)Nc1cc(ccc1O)[C@@H](O)CN[C@H](C)Cc1ccc(OC)cc1,
InChI=1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1,
InChIKey=BPZSYCZIITTYBL-YJYMSZOUSA-N
|